Although addition of imatinib, the first-generation ABL1 tyrosine kinase inhibitor, to conventional treatment has improved outcome in children with Philadelphia chromosome (BCR-ABL1)-positive ALL [23–25], refractory or relapsed disease remains a difficult problem in these cases. Here, ABL1 is linked to acute lymphoblastic leukemia.